35536-53-9
35536-53-9
Chemical Structure
11-Deoxy Prostaglandin E2
- CAS No.: 35536-53-9
- Formula:C20H32O4
- Molecular Weight:336.47
IUPAC Name: (Z)-7-((1R,2R)-2-((S,E)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)hept-5-enoic acid
InChIKey: CTHZICXYLKQMKI-FOSBLDSVSA-N
SMILES: CCCCC[C@@H](/C=C/[C@@H](CCC1=O)[C@H]1C/C=C\CCCC(O)=O)O
Biological Activity: 11-Deoxy Prostaglandin E2 is a selective agonist of EP4 with an EC50 of 0.66 nM. 11-Deoxy Prostaglandin E2 is an analog of prostaglandin E2. 11-Deoxy Prostaglandin E2 can be used in study bone healing, heart failure, and other receptor associated conditions[1][2].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
11-Deoxy Prostaglandin E2 | 99.0% | 11-Deoxy Prostaglandin E2 is a selective agonist of EP4 with an EC50 of 0.66 nM. 11-Deoxy Prostaglandin E2 is an analog of prostaglandin E2. 11-Deoxy Prostaglandin E2 can be used in study bone healing, heart failure, and other receptor associated conditions. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.86
HY-12804311-Deoxy prostaglandin E1 -
Similarity Score 0.84
HY-113041Prostaglandin A2 -
Similarity Score 0.84
HY-11489215-A2t-Isoprostane -
Similarity Score 0.84
HY-11670411-Deoxyprostaglandin F2α -
Similarity Score 0.84
HY-12539611-Deoxyprostaglandin F2β -
Similarity Score 0.83
HY-13669611-Deoxy-16,16-dimethyl-PGE2 -
Similarity Score 0.82
HY-113366Prostaglandin J2 -
Similarity Score 0.81
HY-120656Prostaglandin K2 -
Similarity Score 0.80
HY-101952Prostaglandin E2 -
Explore the MedChemAI to find more analogs
References
- [1]. Holt MC, et al. Improved homology modeling of the human & rat EP4 prostanoid receptors. BMC Mol Cell Biol. 2019 Aug 27;20(1):37. [Content Brief]
- [2]. Ungrin MD, et al. Key structural features of prostaglandin E(2) and prostanoid analogs involved in binding and activation of the human EP(1) prostanoid receptor. Mol Pharmacol. 2001 Jun;59(6):1446-56. [Content Brief]
